Skip to main content
Medical Reference · Condition Monograph

Kidney cancer

신장암

Kidney cancer is a term that collectively refers to cancers that begin in the kidney, and the most common form in adults is renal cell carcinoma.

History

Kidney cancer is a term that collectively refers to cancers that begin in the kidney, and the most common form in adults is renal cell carcinoma. Renal cell carcinoma often arises from the cells of the small tubes (tubules) in the kidney that filter and transport the raw materials of urine. In the past, three typical symptoms, flank pain, blood in the urine, and a lump that can be felt in the abdomen, were known as the "classic triad of kidney cancer," and it was common for people to visit a hospital only after these symptoms appeared. However, it gradually became clear that cases in which all three of these symptoms appear are actually rare and usually suggest that the disease is quite advanced.

What greatly changed the flow of care was the spread of imaging tests. Cases in which a small kidney tumor was discovered incidentally while abdominal ultrasound or computed tomography was performed for another reason increased, and as a result, the proportion diagnosed at an earlier stage than in the past grew. This change more clearly showed the fact that "kidney cancer often grows slowly," and it led to the view that surgery removing the entire kidney is not the only answer for small tumors. Surgery has also changed greatly, and recently, when a tumor is small and appropriately located, partial nephrectomy, which preserves kidney function as much as possible, is widely performed.

In the history of treatment of metastatic renal cell carcinoma, advances in drug therapy have been decisive. Recent research shows a trend in which immune checkpoint inhibitors have become established as a pillar of standard treatment, and survival is further prolonged by combining immunotherapy with targeted therapy. As evidence has also been presented that adjuvant immunotherapy can help survival in groups at high risk of recurrence after surgery, kidney cancer treatment has become a field in which both local treatment and systemic treatment are advancing rapidly.

Causes

It is difficult to pin the cause of kidney cancer down to a single factor. However, within the broad framework that "kidney cells accumulate genetic damage and turn into cancer," the factors that increase risk are relatively well known. The representative risk factors are smoking, obesity, and hypertension. These three are linked to lifestyle and chronic diseases, and it is estimated that a considerable portion of all kidney cancers is associated with these factors.

Occupational and environmental exposures also play some role. There are reports that long-term exposure to substances such as certain metals (cadmium, etc.), some solvents, and asbestos can increase the risk. In addition, acquired cystic kidney disease, which develops in patients whose kidney function has severely declined and who undergo long-term dialysis, can greatly increase the risk of renal cell carcinoma.

Most kidney cancers are explained not by a particular "single cause," but as a form in which chronic exposures such as smoking, obesity, and hypertension accumulate over a long period. Therefore, the most important message regarding causes is that "lifestyle and the management of chronic diseases affect the risk of kidney cancer."

Genetic Epidemiology

Most kidney cancers occur sporadically, but there are groups with a clear genetic predisposition. If there is a family member with renal cell carcinoma, the risk increases, and especially when several cases occur among close relatives or the cancer occurs at a young age, a hereditary kidney cancer syndrome is considered.

There are several forms of hereditary kidney cancer. For example, in conditions associated with abnormalities of the von Hippel–Lindau (VHL) gene, the risk of clear cell renal cell carcinoma can increase. Conditions such as Birt–Hogg–Dubé (BHD) syndrome, hereditary papillary renal cell carcinoma, and hereditary leiomyomatosis and renal cell cancer syndrome are also known. In such cases, the risk of tumors in other organs as well as kidney cancer must be considered, so genetic counseling and family screening strategies become important.

Recent research shows an expansion of treatments aimed at the molecular pathways of tumors, such as drugs targeting the hypoxia-inducible factor pathway. However, these treatments do not apply to all patients and depend on the stage of the disease, the type of tumor, and test results.

General Epidemiology

Renal cell carcinoma accounts for most adult kidney cancers. In many cases, it is discovered incidentally when there are no symptoms. In fact, "incidental findings," in which a mass in the kidney is discovered during abdominal imaging performed for another reason, are known to account for a considerable proportion. This also suggests that more diagnoses may be made in regions with greater access to medical care and more frequent imaging.

The risk of kidney cancer increases with age, and it has been reported to tend to be more common in men. Incidence varies by region, with differences in lifestyle (smoking, obesity), chronic diseases, and diagnostic practices (frequency of imaging) acting together. The stage distribution at diagnosis tends toward more cases at relatively early stages, but some are still discovered in a metastatic state.

Recent research shows that immunotherapy-based combination therapy has improved survival in metastatic kidney cancer, but because cure is not easy, it remains a disease that requires long-term management. Stage greatly determines prognosis; treatment outcomes are good when the cancer is confined to the kidney, and when there is metastasis, treatment becomes prolonged.

Pathogenesis

The pathogenesis of kidney cancer can be summarized as "a process in which cell proliferation increases abnormally, blood vessels grow abundantly, and immune evasion occurs." There are several types of renal cell carcinoma, and for the most common, the clear cell type, specific molecular pathways are well known. For example, a widely used explanation is that when an abnormality of the von Hippel–Lindau gene occurs, hypoxia-inducible factor signaling becomes overactive, and substances such as vascular endothelial growth factor increase, which can promote tumor blood vessel formation.

Because of these characteristics, targeted therapy that "inhibits angiogenesis" has long been an important pillar of kidney cancer treatment. In recent research, immune checkpoint inhibitors have been added to this, and the approach of increasing treatment effectiveness by blocking the mechanisms by which tumors evade immunity has advanced. In other words, kidney cancer is a cancer that is easier to understand when the two pillars of blood vessels and immunity are considered together.

In addition, because kidney cancer is molecularly diverse even within "the same renal cell carcinoma," prognosis and treatment response can differ from patient to patient. In recent research, attempts to develop biomarkers for predicting prognosis, molecular classifications, and tools for predicting treatment response are actively under way.

Symptoms

In the early stages, kidney cancer often has no symptoms. That is why it is commonly discovered incidentally during regular checkups or other tests. When symptoms appear, blood in the urine (hematuria), pain in the flank or lower back, and a lump that can be felt in the flank are typically mentioned.

However, this typical combination of symptoms actually appears in only a minority of patients. Many patients may show only systemic symptoms such as fatigue, loss of appetite, weight loss, and low-grade fever, and because these symptoms are also common in other diseases, it is difficult to suspect kidney cancer.

When the cancer progresses and metastases develop, symptoms such as cough or shortness of breath (lung metastasis), bone pain (bone metastasis), and neurological symptoms (brain metastasis) may accompany it. Even when there are metastases, symptoms may be vague at first, so it is important to be evaluated when there are warning signs such as blood in the urine or persistent flank pain.

Signs

On physical examination, there are almost no signs of kidney cancer in the early stages. In advanced cases, a mass may be felt in the flank, the person may look pale due to anemia, or unexplained weight loss may be observed. Kidney cancer can sometimes cause various systemic changes because of "substances secreted by the cancer," which can serve as clues in forms such as elevated calcium, recurrent fever, or night sweats.

In testing, blood in the urine can be an important clue, and blood tests may show anemia or abnormal liver function. However, imaging is central to confirmation. If a kidney mass is seen on ultrasound, contrast-enhanced computed tomography or magnetic resonance imaging is used to evaluate the nature and size of the tumor, invasion of surrounding blood vessels and nearby organs, and the presence of lymph node and distant metastases.

Recent research notes that some small kidney masses seen on imaging may be benign, so if necessary, a kidney mass biopsy may be performed for histological confirmation. However, biopsy is not a test needed by every patient and is chosen when the result will affect the treatment plan.

Screening

Unlike colorectal cancer or cervical cancer, kidney cancer has no established standard screening test for the general population. The reason is that its incidence in the overall population is relatively low, and the balance between the benefits gained from screening and its costs and harms is not clear.

Instead, more active surveillance may be considered for high-risk groups. For example, in people with a hereditary kidney cancer syndrome, or those with acquired cystic kidney disease due to long-term dialysis, strategies for following kidney masses with regular imaging are discussed. In addition, in people who already undergo frequent abdominal imaging for other reasons, the cancer can be diagnosed early through incidental findings.

A realistic approach for the general public is to "be evaluated without delay if there are warning symptoms such as blood in the urine" and to "manage risk factors such as smoking, obesity, and hypertension." It is important for people in high-risk groups to consult with their medical team and establish a surveillance plan tailored to them.

Diagnosis

The diagnosis of kidney cancer usually begins with imaging. In many cases, a mass is discovered when ultrasound is performed because of blood in the urine or flank pain, or it is found incidentally on computed tomography performed to evaluate another condition. After that, contrast-enhanced computed tomography or magnetic resonance imaging is used to evaluate whether the tumor is rich in blood vessels, whether it is cystic, and whether it has spread to surrounding areas, to judge the likelihood of malignancy and the stage.

Additional tests such as chest imaging (to evaluate lung metastasis) may be performed to check for metastasis. Biopsy is not required in all patients, but it may be considered when confirmation of the tumor's nature is needed in order to plan observation or local treatment instead of surgery, when a metastatic lesion is discovered first and the primary lesion needs to be confirmed, or when the diagnosis is unclear from imaging alone.

After confirmation, the stage (tumor size, lymph nodes, presence of metastasis) and tumor grade determine the prediction of prognosis and the treatment plan. In metastatic kidney cancer, prognostic group classification (e.g., the International Metastatic RCC Database Consortium classification) can be used in choosing treatment.

Treatment

Treatment of kidney cancer varies according to the stage and the patient's condition. For small tumors confined to the kidney, partial nephrectomy, which preserves kidney function, is considered first when possible. If the tumor is large or unfavorably located, radical nephrectomy, which removes the entire kidney, may be necessary. When surgery is difficult or the surgical risk is high, local treatment (cryotherapy, radiofrequency treatment, etc.) may be chosen, and for very small tumors judged to be growing slowly, active surveillance is also possible.

In metastatic kidney cancer, systemic treatment becomes central. In recent research, immune checkpoint inhibitors alone or in combination with targeted therapy that inhibits angiogenesis have become established as an important pillar of first-line treatment. The drug combination varies according to the patient's prognostic group, the extent of metastasis, comorbidities, and ability to tolerate side effects. In some patients, the role of "cytoreductive nephrectomy," which removes the primary kidney tumor, is discussed, and the decision is made selectively by considering the treatment response and overall condition together.

Evidence has been presented that adjuvant immunotherapy can reduce recurrence and help survival in some patients at high risk of recurrence after surgery. However, because not all adjuvant treatments show the same effect, selecting the appropriate patients is important.

Prognosis

The prognosis of kidney cancer depends greatly on the stage at diagnosis. At stages confined to the kidney, treatment outcomes are good, and it is known that, particularly when partial nephrectomy is performed for small tumors, the cancer-specific survival rate is very high. Conversely, when there is metastasis to the lymph nodes or other organs, the prognosis worsens.

However, recently there has been a trend of improving treatment outcomes even in metastatic kidney cancer. In recent research, results are accumulating in which immune checkpoint inhibitor–based combination therapy produces long-lasting responses in some patients and prolongs overall survival. Nevertheless, treatment resistance can still develop in many patients, so long-term treatment strategies and management of side effects are important.

When discussing prognosis, preservation of kidney function is also important. When an entire kidney is removed, the burden on the one remaining kidney increases, which can raise the risk of chronic kidney disease. That is why weighing "cancer treatment and preservation of kidney function" in balance, through partial nephrectomy, local treatment, and active surveillance when possible, is the core philosophy of modern kidney cancer treatment.

Prevention

Because the lifestyle-related risk factors for kidney cancer are relatively clear, the focus of prevention is also set on them. Quitting smoking is one of the most important methods of prevention. Maintaining body weight within a healthy range, exercising regularly, and controlling hypertension well are also understood to lower the risk. In addition, preventing and managing chronic kidney disease and reducing unnecessary exposure to chemicals can also be helpful.

In high-risk groups such as long-term dialysis patients, regular imaging follow-up after consultation with the medical team helps with early detection. For people with a hereditary kidney cancer syndrome, genetic counseling together with risk assessment of family members, regular imaging, and checks for other associated tumors are important.

In the end, prevention of kidney cancer can be summarized as "lifestyle management + tailored surveillance for high-risk groups." Avoiding smoking, maintaining a healthy weight, and being evaluated by a specialist without delay when warning symptoms such as blood in the urine appear are the most realistic prevention strategies.

This content is provided for general medical information only and does not replace individual diagnosis or treatment. If symptoms persist, please consult a medical professional.